Zhejiang Ausun Pharmaceutical Co., Ltd. (SHA:603229)
China
· Delayed Price · Currency is CNY 9.64
-0.54 (-5.30%)
Apr 29, 2026, 3:00 PM CST
SHA:603229 Ratios and Metrics
Market cap in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2020 - 2016 |
|---|---|---|---|---|---|---|---|
Period Ending | Apr '26 Apr 28, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | 2020 - 2016 |
| Market Capitalization | 8,432 | 8,217 | 8,295 | 7,834 | 9,564 | 10,451 | Upgrade
|
| Market Cap Growth | 22.95% | -0.94% | 5.87% | -18.09% | -8.49% | 19.25% | Upgrade
|
| Enterprise Value | 7,662 | 7,458 | 7,572 | 7,115 | 9,183 | 9,848 | Upgrade
|
| Last Close Price | 10.18 | 9.92 | 9.88 | 9.22 | 11.80 | 12.88 | Upgrade
|
| PE Ratio | 63.63 | 62.93 | 40.11 | 30.86 | 40.64 | 71.62 | Upgrade
|
| Forward PE | 32.32 | 20.19 | 16.29 | 22.58 | 34.87 | 54.34 | Upgrade
|
| PS Ratio | 10.64 | 10.37 | 10.43 | 9.59 | 12.51 | 18.35 | Upgrade
|
| PB Ratio | 3.72 | 3.62 | 3.65 | 3.66 | 6.55 | 8.33 | Upgrade
|
| P/TBV Ratio | 3.98 | 3.88 | 3.92 | 3.94 | 7.36 | 9.58 | Upgrade
|
| P/FCF Ratio | 161.96 | 157.82 | 124.50 | 134.20 | - | - | Upgrade
|
| P/OCF Ratio | 53.88 | 52.50 | 46.62 | 35.32 | 79.33 | 60.10 | Upgrade
|
| EV/Sales Ratio | 9.67 | 9.41 | 9.52 | 8.71 | 12.01 | 17.29 | Upgrade
|
| EV/EBITDA Ratio | 36.00 | 35.04 | 30.50 | 24.96 | 38.32 | 54.04 | Upgrade
|
| EV/EBIT Ratio | 55.27 | 53.80 | 40.78 | 29.10 | 44.75 | 64.70 | Upgrade
|
| EV/FCF Ratio | 147.17 | 143.25 | 113.66 | 121.89 | - | - | Upgrade
|
| Debt / Equity Ratio | 0.21 | 0.20 | 0.12 | 0.14 | 0.17 | 0.09 | Upgrade
|
| Debt / EBITDA Ratio | 2.23 | 2.15 | 1.09 | 1.06 | 1.01 | 0.60 | Upgrade
|
| Debt / FCF Ratio | 19.02 | 8.77 | 4.09 | 5.19 | - | - | Upgrade
|
| Net Debt / Equity Ratio | -0.28 | -0.34 | -0.36 | -0.38 | -0.25 | -0.45 | Upgrade
|
| Net Debt / EBITDA Ratio | -3.06 | -3.62 | -3.33 | -2.88 | -1.55 | -3.10 | Upgrade
|
| Net Debt / FCF Ratio | -26.11 | -14.79 | -12.40 | -14.06 | 2.45 | 4.12 | Upgrade
|
| Asset Turnover | 0.25 | 0.26 | 0.27 | 0.31 | 0.37 | 0.35 | Upgrade
|
| Inventory Turnover | 0.97 | 0.92 | 0.98 | 1.09 | 1.32 | 1.21 | Upgrade
|
| Quick Ratio | 2.08 | 1.87 | 1.92 | 1.63 | 1.01 | 1.40 | Upgrade
|
| Current Ratio | 2.64 | 2.47 | 2.53 | 2.17 | 1.53 | 1.92 | Upgrade
|
| Return on Equity (ROE) | 4.56% | 5.75% | 9.37% | 14.09% | 17.33% | 12.25% | Upgrade
|
| Return on Assets (ROA) | 2.81% | 2.86% | 3.91% | 5.80% | 6.17% | 5.91% | Upgrade
|
| Return on Invested Capital (ROIC) | 8.79% | 8.91% | 11.56% | 17.71% | 21.20% | 24.91% | Upgrade
|
| Return on Capital Employed (ROCE) | 5.80% | 5.90% | 8.00% | 11.20% | 13.10% | 11.60% | Upgrade
|
| Earnings Yield | 1.55% | 1.59% | 2.49% | 3.24% | 2.46% | 1.40% | Upgrade
|
| FCF Yield | 0.62% | 0.63% | 0.80% | 0.74% | -1.58% | -1.31% | Upgrade
|
| Dividend Yield | 0.98% | - | 1.01% | 1.00% | 0.48% | 0.29% | Upgrade
|
| Payout Ratio | 69.41% | 69.41% | 40.73% | 22.63% | 16.00% | 13.69% | Upgrade
|
| Buyback Yield / Dilution | 1.34% | 1.34% | -0.99% | -1.92% | -1.16% | -6.67% | Upgrade
|
| Total Shareholder Return | 2.33% | 1.34% | 0.02% | -0.92% | -0.68% | -6.38% | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.